Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/31114
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLinares, Raquel-
dc.contributor.authorGutiérrez, Ana-
dc.contributor.authorMárquez-Galera, Ángel-
dc.contributor.authorCaparrós, Esther-
dc.contributor.authorAparicio, José R.-
dc.contributor.authorMadero, Lucía-
dc.contributor.authorPayá, Artemio-
dc.contributor.authorLópez-Atalaya, José P.-
dc.contributor.authorFrancés, Rubén-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-02-05T18:09:12Z-
dc.date.available2024-02-05T18:09:12Z-
dc.date.created2022-
dc.identifier.citationBiomedicine Pharmacotherapy . 2022 Mar:147:112653es_ES
dc.identifier.issn1950-6007-
dc.identifier.urihttps://hdl.handle.net/11000/31114-
dc.description.abstractBackground: Crohn's disease (CD) exacerbation is marked by an intense cellular trafficking. We set out to determine the specific impact of biologic therapies on regulating chemokine network gene expression in healthy, mildly and severely inflamed tissue of CD patients.Methods: Twenty CD patients on biologics (adalimumab, ustekinumab, vedolizumab) or untreated undergoing colonoscopy due to clinical symptoms of flare. Healthy, mildly and severely inflamed ileum biopsies from each patient were collected. Chemokines and receptors gene expression was analyzed and a STRING analysis for functional enrichment was performed.Results: The chemokine network exhibited wide transcriptional differences among tissues in active untreated patients, whereas all biologic treatments reduced these differences and homogenized their transcriptional activity. In mildly inflamed tissue, all treatments showed gene upregulation while ustekinumab additionally maintained the downregulation of genes such as CCL2, CCL3, CCL17 or CCL23, involved in T cell chemotaxis, inflammatory monocyte and NK trafficking. In severely inflamed tissue, all treatments shared a downregulatory effect on chemokines controlling T cell response (i.e. CXCL16, CXCR3). Adalimumab and vedolizumab significantly reduced the expression of genes promoting antigen presentation by DCs and the initiation of leukocyte extravasation (i.e. CXCL12, CCL25, CCR7). Ustekinumab significantly reduced genes positively regulating Th1 cytokine production and IL-8 mediated signaling (i.e. IL1B, XCL1, CXCR1, CXCR2).Conclusion: Biologic therapies differentially target the chemokine network gene expression profile in the ileal tissue of active CD patients. These results may contribute to better understanding cell homing and to defining future personalized therapeutic strategies for CD patients.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent12es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBiologic treatmentes_ES
dc.subjectChemokineses_ES
dc.subjectCrohn’s diseasees_ES
dc.subjectInflammationes_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes_ES
dc.titleTranscriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn’s diseasees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.biopha.2022.112653es_ES
Appears in Collections:
Artículos Medicina Clínica


Thumbnail

View/Open:
 Transcriptional regulation of chemokine network by biologic monotherapy.pdf

8,53 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???